Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499322 | 0.91 | MAPK14 (0.72) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL4332951 | 0.90 | MAPK14 (0.72) | MAPK14CSNK1DMAPK11MAPK10GSK3B | |
| SCHEMBL4336750 | 0.89 | MAPK14 (0.71) | MAPK14CSNK1DGSK3B | |
| SCHEMBL4340449 | 0.88 | MAPK14 (0.70) | MAPK14CSNK1DGSK3B | |
| SCHEMBL4336207 | 0.88 | MAPK14 (0.78) | MAPK14CSNK1DMAPK11MAPK10GSK3B | |
| SCHEMBL4343964 | 0.86 | MAPK14 (0.75) | MAPK14CSNK1DMAPK11MAPK10 | |
| SCHEMBL4336133 | 0.86 | MAPK14 (0.75) | MAPK14CSNK1DMAPK11MAPK10 | |
| SCHEMBL1878355 | 0.84 | MAPK14 (0.72) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL4337273 | 0.84 | MAPK14 (0.71) | MAPK14CSNK1DMAPK11MAPK10 | |
| SCHEMBL4339293 | 0.84 | MAPK14 (0.71) | MAPK14CSNK1DMAPK11MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576914-B2 | Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof | THE DOSHISHA (JP) | 2023-02-14 | — | — | US | disclosed |
| US-20210008067-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF-ß SIGNALLING, AND APPLICATION THEREOF | THE DOSHISHA (JP) | 2021-01-14 | — | — | US | disclosed |
| EP-3659626-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF- SIGNALLING, AND APPLICATION THEREOF | The Doshisha (JP) | 2020-06-03 | — | — | EP | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576914-B2 | Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof | TGFBR1, FIBP, TGFB1 | MAPK14 133/4885CSNK1D 1853/4885MAPK13 55/4885 |
| US-20210008067-A1 | DRUG FOR TREATING OR PREVENTING DISORDER CAUSED BY TGF-ß SIGNALLING, AND APPLICATION THEREOF | TGFBR1, TGFB1, FIBP | MAPK14 120/4885CSNK1D 1740/4885MAPK13 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.